On the assumption that the receptor tyrosine kinase (RTK) FGFR1 is the driver of the 8p11.2-p12 amplicon and represents a potential drug target in a variety of cancers, RTK-targeting small-molecule inhibitors against FGFR1 such as ponatinib, dovitinib, PD173074, and SU5402 were designed, and knockdown and preclinical pharmaceutical inhibition studies were carried out [2, 5, 10, 23, 31, 47, 62]. This evidence concerns the gene FGFR1 and cancer.